Novel biomarkers for diagnostics and drug R&D: What is industry looking for?

Novel Biomarkers for Diagnostics and Drug
R&D – What is industry looking for?

Tom Metcalfe, F. Hoffmann-La Roche AG
Ontario Genomics Institute, Markers to Markets Workshop,
Toronto, June 22nd, 2010

"#$%&'#()*

+,)-%./0)/0-.1-0,#$-2*)$)/0'0#./-*)2*)$)/0$-0,)-
2)*$./'&-.2#/#./$-.1-0,)-2*)$)/0)*-'/3-/.0-
/)%)$$'*#&4-0,.$)-.1-5.%,)

!

+,)-2)*$2)%0#7)-.1-0,)-8,'*('%)90#%'&$-:9$#/)$$

6

A"B)C(1D"(+)50)8&#/<")1/)%&")*&#(7#)E/?,+%(B

!"#$%&'#(")*("++,("+- 6'5/571')*("++,("+- 9":);"'&/5$5<1"+-
."/"01%231+4)3#%15 85+%2."/"01%)3#%15 6=>#/?"?)8#>#@1$1%1"+

;

A"B)C(1D"(+)50)8&#/<")1/)F,()E/?,+%(B
A call for more effective and safer drugs

6001'#'B J#0"%B

I/#$<"+1'+
C(,<)3"+>5/+")3#%"G)H
L>M
IB

>'/.1# '7)/0#$
JB

K.7'*0#$
;B
8#/'"(

:'4)*
!B

K.7'*0#$
B

=->2)'*$-)0-'&?@-+*)/3$-A.&-A)3@-!BB=C-!-D'E'*.9 )0-'&?@-FGAG@-=HHI <

A"B)C(1D"(+)50)8&#/<")1/)F,()E/?,+%(B
Economic pressures intensify focus on improved
benefit-cost ratio
R?>?-Q)'&0,%'*)->2)/3#/S@-R>T-:#&&#./$- R?>?-Q)'&0,%'*)->2)/3-'$-U-.1-L"8

OMMM

NMH

NLMM KP
KOH H
KLMM

!BBB !BBI !B=< !BBB !BBI !B=<

>.9*%)N-O)/0)*$-1.*-A)3#%'*)-'/3-A)3#%'#3@-P11#%)-.1-0,)-G%09'*4@-K'0#./'&-Q)'&0,->0'0#$0#%$-L*.92 J

A"B)C(1D"(+)50)8&#/<")1/)F,()E/?,+%(B)
Step-change needed in Pharma R&D

LX 9":)R5$"',$#()6/%1%1"+)S9R6T
U)OV)./)

NO
NK
U)KV)./)
KW)

KWWP) NMMV MY MW
3QC)J>"/?
>.9*%)$N-W"GXO"Y5 "'0'@-8,5AG 3'0'@-8*#%)-Z'0)*,.9$)-O..2)*$-'/'&4$#$@-8,'*('-!B!B V

6D5$,%15/)50)R"?1'1/")[)[)[)#/?)*!8
Progress in therapy driven by new technologies
6D5$,%15/)50)R"?1'1/"

Z,%,("
!
;5?#B JB+%"7+).15$5$#/%#%15/
R5?"(/ 8(1%1'#$)8#("
R"?1'1/"
R1'(5@15$5" I/#$B]"(+ S1["[)*83T 1/05(7#%1'+
I

A"B)C(1D"(+)50)8&#/<");5:#(?+)*"(+5/#$1+"?
!"#$%&'#(")S*!8T
PHC is key to enabling highly differentiated
medicines

!"#$%&'#(")*("++,("+- 6'5/571')*("++,("+- 9":);"'&/5$5<1"+-
."/"01%231+4)3#%15 ."/"01%285+%)3#%15 6=>#/?"?)8#>#@1$1%1"+

9""?)05()&1<&$B)?100"("/%1#%"?)7"?1'1/"+
%&#%)>5+1%1D"$B)17>#'%)>,@$1')&"#$%&

J5'1"%B)#/?)>#B5(+ :1$$)(":#(?)+1</101'#/%)1//5D#%15/
H

`&#%)1+)*"(+5/#$1+"?)!"#$%&'#("a
Encompasses many actions to improve patient outcomes
.(5#?"+%)+"/+"
[ P20#('&-'3'20'0#./-.1-,)'&0,%'*)-3)%#$#./$-QO-('#/0)/'/%)@-(./#0.*#/S@-
2*)7)/0'0#7)-'/3-0,)*'2)90#%-$0)2$]-^'$)3-./-'-2)*$./_$-#/3#7#39'&-
%,'*'%0)*#$0#%$@-,)'&0,%'*)-$0'09$-'/3-2)*$./'&-$#09'0#./?
[ `/%&93)$-0,)-9$)-.1-3#'S/.$0#%$@-%,.#%)-.1-0,)*'24@-%,.#%)-.1-3.$)@-0#(#/S-'/3-
1*)a9)/%4-.1-3.$)
Z5()'57>#/1"+)1/)%&")>&#(7#b@15%"'&)1/?,+%(B):5(4+>#'"
[ 8,'*('-'/3-:#.0)%,@-#/-0,)#*-%'2'%#04-'$-#/39$0*4-()(^)*$-b,#%,-3#$%.7)*@-
3)7)&.2-'/3-('*c)0-#//.7'0#7)-()3#%#/)$-'*)-$0*./S&4-2.$#0#./)3-0.-#(2'%0-'-
%*#0#%'&-2'*0-.1-8)*$./'&#$)3-Q)'&0,%'*)
[ Y/$9*)-0,'0-b)-3)7)&.2-.9*-()3#%#/)$-#/-'-b'4-0,'0-b)-9/3)*$0'/3 b,#%,-
S*.92$-.1-2'0#)/0$-3)*#7)-0,)-(.$0-/)0-^)/)1#0-)11#%'%4-'/3-$'1)04]-1*.(-0,)-
/.7)&-()3#%#/)$-0,'0-b)-3)7)&.2

=B

*"(+5/#$1+"? !"#$%&'#(")#/?)C(,<
C1+'5D"(B)#/?)C"D"$5>7"/%
!"#$%&'()#'#*+,-.$/+-,*0$&1$+"#$0-23$0#4#)&('#*+$(-&%#//

C"%"(71/1/<)
C"D"$5>1/<) :&1'&)<(5,>+)50)
1//5D#%1D") >#%1"/%+)?"(1D")
7"?1'1/"+ 75+%)@"/"01%)0(57)
%&")/":)7"?1'1/"

==

J57")50)%&")>(571+"+)50)*"(+5/#$1+"? !"#$%&'#("
Can we deliver on all of them?

[ `//.7'0#7)-()3#%#/)$-b,#%,-'*)-^)00)*-0'*S)0)3-0.-0,.$)-(.$0-&#c)&4-
0.-*)$2./3-'/3-'*)-$'1)*-'/3-(.*)-)11#%'%#.9$-0,'/-%9**)/0-
()3#%#/)$-!
[ G/-#/%*)'$)3-9/3)*$0'/3#/S-.1-,9('/-2'0,.2,4$#.&.S4 '/3-0,)-
(.&)%9&'*-^'$#$-.1-3#$)'$)-!
[ `(2*.7)3-2'0#)/0-3#'S/.$)$-!
[ `(2*.7)3-2'0#)/0-%'*)-!
[ A.*)-)11#%#)/0-9$)-.1-,)'&0,%'*)-*)$.9*%)$-! d
[ >,.*0)*-'/3-&)$$-)e2)/$#7)-%&#/#%'&-0*#'&$d
=!

J57")50)%&")75+%)7#c5()'&#$$"/<"+)50)?"$1D"(1/<)
*"(+5/#$1+"? !"#$%&'#("dd

[ `(2*.7)3-9/3)*$0'/3#/S-.1-,9('/-2'0,.2,4$#.&.S4 '/3-0,)-(.&)%9&'*-^'$#$-.1-3#$)'$)-#$-'-
!"#$%&%" '%#()*+,)#"#)1.*-('c#/S-2*.S*)$$-#/-8QO

[ 8'0#)/0$-/))3-0.-^)-%&.$)&4-#/7.&7)3-f b#0,.90-2'0#)/0$-%./$)/0#/S-0.-^)-#/7.&7)3-#/-%&#/#%'&-
*)$)'*%,-2*.S*'($-'/3-3./'0#/S-^#.&.S#%'&-$'(2&)$-f ^&..3@-09(.9*-0#$$9)-)0%?-(9%,-.1-
0,)-b.*c-#$-/.0-2.$$#^&)

[ :.0,-8,'*('-'/3-"#'S/.$0#%$-#/39$0*4-()(^)*$-(9$0-('c)-'-/9(^)*-.1-%.(2&)e-
.*S'/#E'0#./'&-'/3-&.S#$0#%'&-'3'20'0#./$

[ `//.7'0#7)-*)S9&'0.*4-'22*.'%,)$-'*)-*)a9#*)3-O*#0#%'&-8'0,-`/#0#'0#7)-)0%?]

[ Ye0)/$#7)-OAY-2*.S*'($-b#&&-^)-*)a9#*)3-#1-2,4$#%#'/$-'*)-0.-('c)-0,)-(.$0-.90-.1-8QO

[ `(2*.7)3-3)%#$#./-$922.*0-$4$0)($-1.*-2,4$#%#'/$-'/3-.0,)*$

[ >#S/#1#%'/0-#//.7'0#./-#/-0,)-"#'S/.$0#%$-('*c)02&'%)-f ^.0,-1*.(-`g"--'/3-#('S#/S-
)a9#2()/0-$922&#)*$-'/3-1*.(-%&#/#%'&-&'^$-'
=6

8&,%"+)#/?)e#??"(+)5/)%&")8(1%1'#$)*#%&-)857>#(#%1D")
600"'%1D"/"++G)*(5?,'%)^#$,"G)#/?)%&")f+")50).157#(4"(+)1/)
C(,<)C"D"$5>7"/%

[ +,)-#(2)*'0#7)-0.-2*.39%)-,#S,h7'&9)@-#//.7'0#7)-3*9S$-b#&&-#/0)/$#14@-
%*)'0#/S-'-,#S,)*-2)*1.*('/%)-,9*3&)-1.*-/)b-0,)*'2)90#%$?-:'$#%
^#.()3#%'&-$%#)/%)-b#&&-!-+.#)"+&)!,#$%$,&()/%"0,.1(.' b#0,-
0'/0'&#E#/S-2.0)/0#'&-0.-#(2*.7)-7'&9)@-b,)*)'$-()0,.3$-0.-9$)-0,)(-
)11)%0#7)&4-#/-$.+2)$(3(4"50(#&)6%44)(3"43()0".()'4"647?-+,)-^'&'/%)-
^)0b))/-0,)$)-1.*%)$-('4-b)&&-3)0)*(#/)-0,)-$9%%)$$-.*-1'#&9*)-.1-
0,)-3*9S-3)7)&.2()/0-)/0)*2*#$)-.7)*-0,)-/)e0-3)%'3)?

F?-Z..3%.%c@-O&#/?-8,'*(?-'/3-+,)*?-!BBH]C-IJ@-=@-=!f=;? =;

857>5/"/%+)50)*!8
Key steps to bringing new value to the practice of
medicine

" R/3)*$0'/3-,)0)*.S)/)#04-.1-3#$)'$)$

# "#$%.7)*-'/3-3)7)&.2-.(4(3,#&)/%"0,.1(.'

$ >0*'0#14-2'0#)/0$-b#0,-3#'S/.$0#%-0)$0$

% :9#&3-)7#3)/%)-1.*-^)00)*-^)/)1#0h*#$c-*'0#.

=<

*!8)1+)#%)%&")'5(")50)35'&"g+)/":)#>>(5#'&)%5)C(,<)
C1+'5D"(B)#/?)C"D"$5>7"/%

3"+"#('& C"D"$5> 8577"('1#$1]"
D)'3- A'*c)0
+'*S)0
L)/)*'0#./X- 8,'$)-B 8,'$)-` 8,'$)-`` 8,'$)-``` W#&#/S
>)&)%0#./
P20#(#E'0#./ 8,'$)-`g

"#$%.7)*4
Ye2&.*'0.*4-8,'$) 8.O O./1#*('0.*4-8,'$)
8,'$) ! ! ! ! !
:#.('*c)* O.(2'/#./-3#'S/.$0#% "e-&'9/%,X-8.$0h&'9/%,-
)e2&.*'0#./ 1)'$#^#&#04-i-'00*'%0#7)/)$$ '$$)$$()/0
+'#&.*)3-2*)$%*#^#/S
+'*S)0-#3)/0#1#%'0#./ 8'0#)/0-$)&)%0#./ i-(./#0.*#/S

3"+"#('&)#++#B ;"'&/1'#$$B)D#$1?#%"?)#++#B 8$1/1'#$$B)D#$1?#%"?)E^C)#++#B
=J

C(,<)?"D"$5>7"/%)#/?)'57>#/15/)?1#</5+%1')
?"D"$5>7"/%)#(")50%"/)/5%)#$1</"?
*&#(7#)3QC)>(5'"++)

8$1/1'#$)
Q)?"'1+15/)>51/%+

8#/?1?#%") 6/%(B)E/%5)
J"$"'%15/ !,7#/ Z1$1/<

C1+'5D"(B 6=>$5(#%5(B))))))))))))))))))))) 85/01(7#%5(B)))))))))))))))))))))))
*&#+" *&#+" *58 *&#+"
.157#(4"()C1+'5D"(B)

.157#(4"()8#/?1?#%"+)))))))))))))))) .157#(4"()8#/?1?#%"+)C1+'5D"(BN-
C1+'5D"(B K.7)&-,42.0,)$#$h L)/)*'0#/S-$0*'0)S4
Q)C"D"$5>7"/%

;"'&/1'#$b)8$1/1'#$)^#$1?#%15/-)
;"'&/1'#$b)))))))))))))))))) Q42.0,)$#$-#$-^)#/S-7'&#3'0)3-X-)/0)*#/S-
8$1/1'#$))))))))))))))))))))))
%&#/#%'&-7'&#3'0#./
^#$1?#%15/

E^C)C"D"$5>7"/%N-:#.('*c)*-'$$'4-#/-
%&#/#%'&-7'&#3'0#./
E^C)C"D"$5>7"/%
=V

35'&"g+)3"+"#('&)#/?)6#($B)C"D"$5>7"/%)R5?"$
Bringing the right disciplines together at the centre of
drug discovery & early development

;(#/+$#%15/#$)R"?1'1/" JB+%"7).15$5(5D"?)
89J
C1+"#+"
^1(5$5<B F/'5$5<B R"%#@5$1')
C1+"#+" E/0$#77#%15/ ,/?"(+%#/?1/<)
50)?1+"#+"
."%%"()
R5?"$1/<)Q)J17,$#%15/ .157#(4"(+ '#/?1?#%")
./'0)*+)1'#'%-2&34'-, 5)6)03-$*$%%6# @157#(4"(+
=I

.157#(4"(+
Essential to enabling translational medicine and drug
development
[ f/?"(+%#/?1/<)>#%&:#B+)#/?)7"'&#/1+7+
)?S?-0'*S)0$@-(.&)%9&'*-()%,'/#$($-'/3-2'0,.2,4$#.&.S4]-

[ E7>(5D"?)?"'1+15/)7#41/<)1/)3QC
)?S?-0..&$-1.*-2*.1#&#/S-0'*S)0$@-%.(2.9/3$@-8"-'/3-$'1)04-
A'*c)*$]

[ C(1D"(+)05()>&#(7#'5?1#</5+%1')?"D"$5>7"/%
)/,'/%#/S-*)$2./$)-*'0)$@-#(2*.7#/S-^)/)1#0X*#$c-*'0#.@-
%.(2'/#./-3#'S/.$0#%$]

=H

.157#(4"(+)#/?)*&#(7#'5?1#</5+%1'+
Biomarkers are essential tools in modern drug development
and key to Personalised Healthcare

Pharmacodiagnostic
Biomarkers
• Treatment eligibility
• Response prediction
• Safety and Efficacy
Biomarkers perspective

Pharmacological Disease
Biomarkers Biomarkers
• Pharmacodynamic • Patient risk
markers • Early detection
• Pharmacokinetic • Prognosis
markers
• Monitoring/
• Mechanism of action Recurrence
markers
!B

h,#$101'#%15/)50)/5D"$)@157#(4"(+

8$1/1'#$)^#$1?1%B I/#$B%1'#$)^#$1?1%B

[ R/3)*$0'/3-7'*#'^#&#04-#/-0,)-()'$9*#/S-
[ R/3)*$0'/3-'/3-'%%.9/0-1.*-^#.&.S#%'&-
$4$0)(
7'*#'^#&#04
[ D#(#0X%./0*.&-$.9*%)$-.1-7'*#'^#&#04
[ `/0)*2*)0-7'*#'^#&#04-#/-0,)-%./0)e0-.1-
#/0)/3)3-9$)

[ O&#/#%'&-90#&#04-)$0'^&#$,)3-^4-9$#/S-'-
7'&#3-^#.('*c)*-#/-0,)-%&#/#%

+,)-GOOY 1*'()b.*c-G/'&40#%'&-7'&#3#04@-O&#/#%'&-7'&#3#04@
O&#/#%'&-90#&#04@-Y0,#%'&@-D)S'&-'/3->.%#'&-%./$#3)*'0#./$]@-#$-'22&#%'^&)
0.-1.*($-.1-(.&)%9&'*-3#'S/.$0#%$-'/3-^#.('*c)*

;&")1/%"/?"?),+")50)%&")@157#(4"()+&#>"+)7,'&)50)%&")?"D"$5>7"/%):5(4)#/?)
/""?+)%5)@")?"'1?"?)#%)#/)"#($B)+%#<"
!=

`&#%)#@5,%)7,$%1>$")7#(4"()>#/"$+a

G33#0#./'&-%.(2&)e#04N
[ Y'%,-()(^)*-.1-0,)-2'/)&-'33$-'/-'33#0#./'&-$.9*%)-.1-
2.0)/0#'&-)**.*-h0*'3)h.11$-#/-'33)3-$)/$#0#7#04-'0-2.0)/0#'&-%.$0-
0.-$2)%#1#%#04-(9$0-^)-('3)
[ O./0*.&-1.*-#/0)*1)*)/%)-^)0b))/-)'%,-#/3#7#39'&-()(^)*-.1-0,)-
2'/)&
[ `/%*)'$)3-%./$0*'#/0$-./
f >'(2&)-%.&&)%0#./@-2*)2'*'0#./-'/3-$0.*'S)
f A)'$9*)()/0-$4$0)(
f O./0*.&@-%'&#^*'0#./@-$0'/3'*3#E'0#./-%./%)20$

[ O.&&)%0#/S-3'0'-./-0,)-^#.('*c)*-2'/)&_$-2)*1.*('/%)-#/-0,)-
#/0)/3)3-$)00#/S@-'22&#)3-0.-0,)-#/0)/3)3-%&#/#%'&-2.29&'0#./-
!!
)$$)/0#'&

.157#(4"()C1+'5D"(B)Q)C"D"$5>7"/%
Analytical validation/quality needs differ according
to intended use

;"'&/1'#$)b)
.157#(4"()8#/?1?#%"+)C1+'5D"(B E^C)C"D"$5>7"/%
8$1/1'#$)D#$1?#%15/

95[)50).157#(4"(+)#/?)I++#B+
h,#$1%B)("_,1("7"/%+)S'$1/1'#$)#/?
#/#$B%1'#$)D#$1?1%B)50)#++#B+T

!6

Z5',+)5/),/?"(+%#/?1/<)?1+"#+")#%)%&")75$"',$#()$"D"$
Increased effort to understand disease biology and translational
medicine to achieve PHC
"[<[))F/'5$5<B-)

[ `")&#D")17>(5D"?)>(5'"++"+)05()>#%1"/%)+#7>$")'5$$"'%15/
f '()/3)3-`/1.*()3-O./$)/0@-('/3'0.*4-$'(2&)-%.&&)%0#./-
$0*'0)S#)$

[ `")&#D")1/'("#+"?)5,()"005(%)1/)>("'$1/1'#$)>(501$1/<
f #/%*)'$)3-3)20,-.1-2*)%&#/#%'&-2*.1#&#/S-./-%&9$0)*$-.1-
(.&)%9&)$ )?S?-'/0#h'/S#.S)/)$#$]-#/%&93#/S-('*c)0)3-.*-
&'0)-$0'S)-(.&)%9&)$

[ `")&#D")"=>#/?"?)5,()>#(%/"(+&1>+):1%&)#'#?"71')
'577,/1%1"+
f +*'/$&'0#./'&-A)3#%#/)-Q9^-#/->#/S'2.*)-.2)*'0#./'&#E)3 #/-
)'*&4-!B=B

!;

8$1/1'#$),%1$1%B)50)("+>5/+")>("?1'%15/
5&'#$6#.$1,%+&-/

[ 5#$c$-'/3-^)/)1#0$-*)&'0)3-0.-jY(2#*#%-G22*.'%,_
f 2*)$9(20#7)-0*)'0()/0-7)*$9$-0)$0-'/3-0*)'0
f /'09*)-.1-#&&/)$$-'%90)@-&#1)h0,*)'0)/#/S]-'/3-0*)'0()/0-'&0)*/'0#7)$
[ +,)*'2)90#%-*)$2./$)-*'0)
f 5)&'0#7)&4-,#S,-kJBU]-.*-&.b-l-6BU]?
[ 5)&'0#7)-%.$0$
f 0.0'&-%.$0-.1-'%a9#*#/S-0)$0-#/1.*('0#./-0#()-'/3-(./)4]-7)*$9$ $'7#/S$-1*.(-
0)$0#/S
f 2)*%)#7)3-'33#0#./'&-7'&9)-39)-0.-*)39%0#./-.1-2'0#)/0-9/%)*0'#/04
[ 5)&'0#7)-2*)3#%0#7)-7'&9)
f ,.b-b)&&-3.)$-0,)-0)$0-#/1.*(-%&#/#%'&-3)%#$#./-('c#/Sd
[ `$$9)$-*)&'0)3-0.-('*c)0-'%%)20'/%)X2*'%0#%'&#04
f 0)$0-2&'01.*(-'7'#&'^#&#04@-2,4$#%#'/-)39%'0#./-'/3-'%%)20'/%)-)0%?

!<

J57"%17"+)+%#(%1/<)>51/%)05()("+>5/+")7#(4"(+)5@D15,+[[
MDM2 Biomarker Program

• MDM2 is the master regulator of
p53
• Antagonists of p53-MDM2
binding can activate the p53
pathway and restore cell cycle
MDM2 inh binds to MDM2 min the p53 binding
arrest and apoptosis pocket

[ A"A! '/0'S./#$0$-b#&&-&#c)&4-/.0-^)-^)/)1#%#'&-1.*-2'0#)/0$-b#0,-09(.*$-(90'0)3-1.*-2<6
'22*.e-<B-U-.1-,9('/-09(.*$]
[ 8'0#)/0-$0*'0#1#%'0#./-^4-2<6-S)/)-$0'09$-*)a9#*)3-0.-#3)/0#14-2.0)/0#'&-*)$2./3)*$

Roche Diagnostics developing a test
platform for p53 resequencing

p53 AmpliChip !J
Roche RMD

;#(<"%1/<).3IZ R,%#%15/+)1/)8#/'"(
One promising early phase example

[ ;5<= <"/")7,%#%15/+)?"%"'%"?)1/)iVH)50)#$$)
'#/'"(+
f R2-0.-VBU-.1-('&#S/'/0-()&'/.('$
f R2-0.-<6U-.1-2'2#&&'*4-0,4*.#3-%'*%#/.('$
f R2-0.-=<U-.1-%.&.*)%0'&-09(.*$

[ R5+%)'5775/)7,%#%15/)@B)0#(-)^PMM6)1/)"=5/)KL
f n-VBU-()&'/.('$@-0,4*.#3-'/3-%.&.*)%0'&-%'/%)*$--
b#0,-(90'0)3-=>?@
5GW-'%0#7'0)$-0,)-AG8M-$#S/'&#/S-2'0,b'4
:5GW-%'/-^)-'%0#7'0)3-^4-'-$#/S&)-(90'0#./-gJBBY] *eOMXN N-K.7)&-$('&&h(.&)%9&)-
#/,#^#0.*-1*.(-8&)ee#c./
85C=)/""?N-+'a('/o 8O5h^'$)3-
8)94%#):#!"4)!6NJVV=-!BB<]-A-:))*'( (&),4;<)9,#!(.)9(44)JN6=6-!BB;]-AF-L'*/)00-'/3-5-A'*'#$- gJBBY (90'0#./-3)0)%0#./ !V

C"01/1/<)("+>5/+")1/)>#%1"/%+):1%&)3&",7#%51?)I(%&(1%1+
3"+>5/+")7"#+,("?)@B)'57>5+1%")+'5("+
f I83)S17>(5D"7"/%)/5%)#'%1D1%BT
[ GO5!B-f '-!BU-#(2*.7)()/0-#/-+FO-'/3->FO-'/3-#/-6-.1-0,)-1.&&.b#/S-
f 8'0#)/0-S&.^'&-'$$)$$()/0
f 8,4$#%#'/$-S&.^'&-'$$)$$()/0
f 8'0#)/0$-'$$)$$()/0-.1-2'#/
f ")S*))-.1-3#$'^#&#04-
f D)7)&-.1-'%90)-2,'$)-*)'%0'/0$

f CIJ)S17>(5D"7"/%)#/?)#'%1D1%BT
[ `/%&93)$-'*0#%9&'*-#/3)e@->FO@-Y>5@-8'0#)/0-S&.^'&-'$$)$$()/0
f L..3-*)$2./$)-"G>-l!?;C-"k=?!
f K./h*)$2./3)*-"G>-k6?VC-"lB?J

f C100"("/%)%&"(#>1"+)7#B)>(5?,'")?100"("/%)"00"'%+)5/)%&")'57>5/"/%+)50)#)
'57>5+1%")+'5(")j #/?)%&"("05(")5/)%&")7"#+,("7"/%)50)("+>5/+"

!I

C1+'5D"(1/<)#/?)1/%"<(#%1/<)/5D"$)("+>5/+")
7#(4"(+)1/%5)?(,<)?"D"$5>7"/%
O,'&&)/S)$m
[ O.**)&'0#./-.1-/.7)&-('*c)*$-b#0,-*)$2./$)-*)a9#*)$-0,'0-0,)*)-^)-$911#%#)/0-
*)$2./3)*$-#/-)'*&4-3)7)&.2()/0
[ ".-b)-,'7)-0,)-*#S,0-*)$2./$)-2,)/.042)d-)?S?-09(.*-*)$2./$)-7)*$9$-
$9*7#7'&
[ ".)$-0,)-('*c)*-3)1#/)-*)$2./$)-2*)3#%0#7)]-.*-'-3#11)*)/0-%.9*$)-.1-3#$)'$)-
2*.S/.$0#%]-.*-^.0,d
[ Q'7)-b)-S.0-'%%)$$-0.-0,)-*#S,0-042)-.1-%&#/#%'&-$'(2&)$d-'/3-,'7)-0,)4-
^))/-$0.*)3-%.**)%0&4m?]
[ Q42.0,)$#$-1*))-'22*.'%,)$-)?S?-ZLG>@-0*'/$%*#20.(#%$]-()'/-0,'0-b)-3./_0-
,'7)-0.-$0'*0-b#0,-'-,42.0,)$#$@-^90-b#&&-&)'3-0.-('/4-1'&$)-p7)_$
[ A'4-.10)/-*)$9&0-#/-$0*'0#1#%'0#./-,42.0,)$)$-^)#/S-3)7)&.2)3-2.$0-#/#0#'&-
&#%)/$#/S-.1-(.&)%9&)m?
!H

E/%"/?"?),+")50)@157#(4"()?"%"(71/"+)("_,1("?)
>"(05(7#/'"
!-,0#$&11/$7*$/#*/7+747+.$4#-/2/$/(#%717%7+.
Serious illness: don’t withhold therapy inappropriately
+ response - response
+ test true positive & false positive
- test ' false negative true negative
Efficacy marker: High sensitivity
+ adverse event - adverse event
+ test true positive ' false positive
- test & false negative true negative
Safety marker: High specificity

Less serious illness: don’t prescribe inappropriately
+ response - response
+ test true positive ' false positive
- test & false negative true negative
Efficacy marker: High specificity
+ adverse event - adverse event
+ test true positive & false positive
- test ' false negative true negative
Safety marker: High sensitivity 6B

*&#(7#'5?1#</5+%1')%"+%)("_,1("7"/%+

[ 3"$1#@$")%"+%+
f &.b-7'*#'^#&#04-h *.^9$0-'/3-*)2*.39%#^&)
f ,#S,&4-2*)3#%0#7)

[ 6#+B)%5)#?71/1+%"(
f b,.&)-^&..3X$)*9(-h ^#.2$4d
f *'2#3-0)$0-09*/'*.9/3
f 7'&9)-.1-0)$0-#/1.*('0#./-.90b)#S,$-'%a9#$#0#./-%.$0$-0#()X%.$0X#/7'$#7)/)$$]

[ `1?"$B)#D#1$#@$"
f '7'#&'^#&#04-.1-0)$0-/.-,#/3*'/%)-0.-('*c)0#/S-.1-3*9S
f 0)$0#/S-2&'01.*(-b#0,-('/4-2&'%)()/0$-.*-&.b-'%a9#$#0#./-%.$0$

[ 85/',(("/%
f '22*.7'&-.1-0)$0-%./%9**)/0-b#0,-3*9S-'22*.7'&

6=

3"_,1("7"/%+)50)#)*&#(7#'5?1#</5+%1')>#(%/"(

[ `/0)*/'0#./'&-2*)$)/%)
f b#3)-%.(()*%#'&-*)'%,
f *)S9&'0.*4-/)0b.*c-1.*-W"GXOYXF'2'/X>"G

[ G%%)$$-0.-^*.'3-*'/S)-.1-0)%,/.&.S#)$
f )e2)*#)/%)-b#0,-*)a9#*)3-0)$0#/S-2&'01.*(
f `8-^'**#)*$-/.-2*.^&)(-f 1*))3.(-0.-.2)*'0)

[ D'*S)-#/$0'&&)3-^'$)-.1-$4$0)($
[ L..3-0*'%c-*)%.*3-#/-3)7)&.2()/0X*)S9&'0.*4-'11'#*$
[ K.-#$$9)$-b#0,-%.(2)0#0#7)-2*.39%0$X*)&'0#./$,#2$

6!

+,)-2)*$2)%0#7)-.1-0,)-"#'S/.$0#%$-:9$#/)$$

66

J5,('"+)50)95D"$)E^C)R#(4"(+)#/?)I$<5(1%&7+
Mix of internal programs, collaborative programs and in-
licensing
E/2$1'"/+1/<)0(57)
E/2&5,+")7#(4"() #'#?"71#G)@15%"'&)5()
?1+'5D"(B)>(5<(#7+ 5%&"()?1#</5+%1')
'57>#/1"+

85$$#@5(#%1D")
35'&")*&#(7# >(5<(#7+):1%&)
@157#(4"()>(5<(#7+ X(? >#(%B)*&#(7#
#'#?"71#)#/?)@15%"'&
'57>#/15/)?1#</5+%1'+ 6;

e#(<")*5(%05$15)50);"+%1/<)*$#%05(7+
Maintenance of existing test portfolio requires
considerable investment

'5@#+k IBBB-
'/'&4E)*-$)*#)$

'5@#+k JBBB-
'/'&4E)*-$)*#)$

'5@#+k ;BBB-
'/'&4E)*-$)*#)$

JB+%"7)*5(%05$15)1/)%&")J"(,7)`5(4)I("#)50)35'&")*(50"++15/#$)C1#</5+%1'+ 6<

95D"$)E^C)#++#B+)4"B)05()%&")E^C)E/?,+%(B
Testing Efficiency and Medical Value key drivers of
innovation & growth
E/+%(,7"/%
E//5D#%15/

;"+%1/<
6001'1"/'B
R"/,
.("#?%&

`5(40$5:
Q)E;

C"D"$5>
9":
85/%"/%
R"?1'#$
^#$," I>>$B
85/%"/%)05(
9":)f+"+

C"'"/%(#$1]"
;"+%1/<
6J

R"?1'#$)^#$,"
Finding & driving new content addressing high
medical needs

C"D"$5> Z5',+)5/-)
>)+'136*?36")
9": [ &)7)&-.1-9/()0-()3#%'&-
85/%"/%
/))3

I>>$B [ 3#$)'$)-^#.&.S4-
85/%"/%)05( 9/3)*$0'/3#/S
9":)f+"+
[ ,)'&0,h)%./.(#%-7'&9)

d :&#%)1%)%#4"+
=? ")7)&.2()/0-i-#(2&)()/0'0#./-.1-%*.$$h:G-3#$)'$)h'*)'-$0*'0)S#)$
!? `(2&)()/0'0#./-.1-'-$4$0)('0#%-2*.%)$$-0.-)11#%#)/0&4-'%%)$$-/)b %./0)/0
[ `3)/0#1#%'0#./-i-1#/3#/S@-'%%)$$#/S-i-$)%9*#/S-"e-`8XW+P@-3)7)&.2#/S-
'$$'4$@-1'$0-i-#/1.*()3-3)%#$#./h('c#/S
6V

I''"++)R"?1#$)^#$,").157#(4"(+)05()F/'5$5%*))/#/S
[ "#'S/.$#$
;("#%7"/%)
[ 8*.S/.$#$
[ 8*)3#%0#./ R#>+
>)+'136*?36") [ A./#0.*#/S

857>#/15/
C1#</5+%1'+

[ +*)'0()/0-$)&)%0#./ R5$"',$#()
l [ 5)$2./$)-2*)3#%0#./ *#%&:#B+

6I

F>>5(%,/1%B)#++"++7"/%
Unmet needs in many areas of patient management

Q)'&0,4 G$4(20.('0#%- >4(20.('0#%-3#$)'$) O,*./#%-3#$)'$)-
3#$)'$) O9*)3

31+4) J'(""/1/<b)
I++"++7"/% C1#</5+1+ *(5</5+%1' *("?1'%1D" R5/1%5(1/<

8*)3#$2.$#0#./- 8*)3#%0- 8*)3#%0-&#c)&4- A./#0.*-
Y'*&4-
1.*-3)7)&.2#/S- 2*.^'^&)- *)$2./$)-0.-'- )11#%'%4X-
3)0)%0#./
3#$)'$) 3#$)'$)-%.9*$) 3*9S *)%9**)/%)

8'0#)/0->0*'0#1#%'0#./-X-+,)*'24->)&)%0#./

+,)*'24-'3'20'0#./
6H

J%(#%"<1')*(15(1%1]#%15/)50)Z5',+)E/?1'#%15/+
8,9&-$:-7+#-7,$

[ A'#/-1.%9$-#$-./-'*)'$-0,'0-'*)-('q.*-%./0*#^90.*$-0.-(.*^#3#04-'/3-
(.*0'&#04-#/-3)7)&.2)3-%.9/0*#)$ $9%,-'$-O'*3#.7'$%9&'*-"#$)'$)$@-
A)0'^.&#%-"#$.*3)*$-)?S?-"#'^)0)$-i-K)2,*.2'0,4@-P/%.&.S4@-
P$0).3)S)/)*'0#7) "#$.*3)*$-'/3-OK>-3#$)'$)

[ G*)'$-b,)*)-#/h7#0*.-&'^.*'0.*4-0)$0$-$)*9(-'$-$'(2&)-.1-%,.#%)]-
'*)-%./$#3)*)3-0.-^)-('q.*-3#'S/.$0#%-%./0*#^90.*$

[ G%0#./'^#&#04 .1-0,)-0)$0-*)$9&0-b#&&-#0-&)'3-0.-'-%,'/S)-#/-2'0#)/0--
%'*)]

[ >0*'0)S#%-1#0-0.-)e#$0#/S-0)$0-()/9

;B

R#c5()h,"+%15/+)05()9":)R#(4"()))))))))))))))))))))
#/?)I$<5(1%&7)C"'1+15/+)

K[ `$-0,)-('*c)*X'&S.*#0,(-'$1/1'#$$B),+"0,$d-`/0)/3)3-9$)-b.*c#/S-
,42.0,)$#$-'/3-'7'#&'^&)-)7#3)/%)-)e#$0#/S-3'0'-.*-3'0'-0.-^)-S)/)*'0)3-
0.S)0,)*-b#0,-$%#)/0#1#%-%.&&'^.*'0#./$]@-#/%&93#/S-'$$)$$()/0-.1-
%.(2)0#0#7)-3#'S/.$0#%-0)%,/.&.S#)$
N[ ".)$-0,)-7#(4"% +1]" q9$0#14-0,)-#/7)$0()/0-.*-2*.7#3)-%.(2)0#0#7)-
'37'/0'S)-#1-2*.39%0-3)7)&.2()/0-%'/-/.0-^)-q9$0#1#)3-'$-$0'/3h'&./)d
X[ G*)-0,)-0)$0$-%"'&/1'#$$B 0"#+1@$" ./-5.%,)-2&'01.*($d
O[ `$-0,)-0)%,/.&.S4-%.7)*)3-^4->#%"/%S+Td
L[ `$-0,)*)-#''"++)%5)#)$1'"/+" '/3-'0-b,'0-%.$0$d
P[ Q.b-^#S-'*)-0,)-*)a9#*)3-"005(%+)05()7#(4"%)?"D"$5>7"/%d
%&#/#%'&-3)7)&.2()/0@-*)S9&'0.*4-'22*.7'&-'/3-('*c)0-3)7)&.2()/0-%.$0$]

;=

9":)R#(4"()J"#('&)Z5',+)05()*(5%"1/)#/?)
R"%#@5$1').157#(4"(+
FD#(B
*(5+%#%" *"$D1')R#++

F/'5$5&(5>#%&B
9IJ!b9IZeC 8#(?15$5+1+
;!

J'5>1/<)50)8#(?15^#+',$#( C1+"#+"
8*.S*)$$#./-.1-G0,)*.$%&)*.$#$ $)%./3'*4 %.(2&#%'0#./$@-

K.-$4(20.($- >4(20.($-.1- >4(20.($-.1-G%90)-
K.-2)*%)20#^&)- K.-$4(20.($- >4(20.($-.1- >4(20.($-.1-G%90)-
K.-2)*%)20#^&)- 3#$)'$)-
C1+"#+") .1-3#$)'$)@- O,*./#%-3#$)'$)- 3#$)'$)- 8.$0h'%90)@-/))3-1.*-
)7#3)/%)- .1-3#$)'$)@- O,*./#%-3#$)'$)- 8.$0h'%90)@-/))3-1.*-
)7#3)/%)- O,)$0-8'#/@->.:@-
+%#<"+ 3#$2&'4-.1-*#$c-1'%0.*$- $0'^&)-'/S#/'@- O,)$0-8'#/@->.:@- $9*7)#&&'/%)X1.&&.b-92
.1-3#$)'$) 3#$2&'4-.1-*#$c-1'%0.*$- $0'^&)-'/S#/'@- >0*.c)@-G%90)-D#(^- $9*7)#&&'/%)X1.&&.b-92
.1-3#$)'$) >0*.c)@-G%90)-D#(^-
$0'S)-G] $,.*0/)$$-.1-^*)'0,] "#$%.(1.*0-OD`]]
$0'S)-G] $,.*0/)$$-.1-^*)'0,] "#$%.(1.*0-OD`]]

;&")/""?)05() >("D"/%15/G)75?10B1/<) %&"(#>B
>("?1+>5+1%15/ ?1#</5+1+ 75/1%5(1/<
%"+%1/< 50)(1+4)0#'%5(+ +%(#%101'#%15/

85/+,7"()l)
>&B+1'1#/a
C5'%5(g+)
*#%1"/%) C5'%5(g+)5001'"
5001'"
+"%%1/<
!5+>1%#$)6Cb88bE8f

I7@,$#%5(Bb)
C#B'#(" ;6

.157#(4"()C"D"$5>7"/%)j 3"_,1("?)8#>#@1$1%1"+
Significant challenges to establishing clinically viable
and useful biomarkers
8577"('1#$1]#%15/
O&#/#%#'/X-D'^-)39%'0#./

G93#0#/S-1.*-*)$9&0-%./$#$0)/%4

"#$0*#^90#./-0.-&'^.*'0.*#)$
^#$1?#%15/b
h,#$101'#%15/ 5)S9&'0.*4-0)$0-'22*.7'&

G$$'4-*)1#/)()/0-i-3)7)&.2()/0-`g"-0)$0

O&#/#%'&-7'&#3'0#./-.1-%'/3#3'0)-('*c)*$-9$#/S-'$$'4
C1+'5D"(B
")7)&.2-2*.0.042)-'$$'4

`3)/0#1#%'0#./-.1-%'/3#3'0)-('*c)*$

L)/)*'0#./-.1-'-^#.('*c)*-,42.0,)$#$ ;;

35'&")C1#</5+%1'+)
;#/73*$:&*+-&)$,*0$:&''#-%7,)7<,+7&*$5+,*0,-0
Analysis Feasibility Development Implementation Manufacturing Sales

C"+1</ C"+1</ C"+1</ e#,/'& 8.$0
>0'*0 D'9/%, D'9/%,
m5#$+ E/>,% F,%>,% C"'1+15/ 5)7#)b

")$#S/-S.'&$@-2*.39%0-7#$#./ W)'$#^#&#04-'22*.7)3 W9/%0#./'&-(.3)&-")7)&.2()/0- 5)2*.39%#^#&#04-2*.7)/
A'*c)0-$#09'0#./-'$$)$$)3 A'*c)0-'/3-%9$0.()*-*)a9#*)()/0$- *)1?-&.0-'22*.7)3- >%'&)h92-%.(2&)0)3@-2*.%)$$)$-
+)%,/#%'&-*)'&#E'0#./-'$$)$$)3 '/'&4E)3 3)$#S/X2)*1.*('/%)] 1#/'&#E)3-'/3-7'&#3'0)3
`/#0#'&-2*.q)%0-2&'/ :9$#/)$$-*)a9#*)()/0$- 8*.0.042)XA'$0)*-2#&.0-&.0- 8*.39%0#./-&.0-3)1#/)3
`/#0#'&-2*.1#0'^#&#04-%,)%c %./$#3)*)3 '22*.7)3 3)$#S/-'/3- 8)*1.*('/%)-7)*#1#%'0#./-'/3
+)%,/#%'&-1)'$#^#&#04-3)(./$0*'0)3 2)*1.*('/%)] )e0)*/'&-7'&#3'0#./-%.(2&)0)3
8*.39%0-'/3-2*.q)%0-*#$c-'$$)$$)3 >2)%#1#%'0#./$-%./1#*()3-#1- A'*c)0#/S-2*)2'*)3
D)S'&-'/3-*)S9&'0.*4-#$$9)$ /))3)3-^4-%9$0.()*$] ")7#%)-('$0)*-*)%.*3
%./$#3)*)3 5p"-3)7#%)-('$0)*-*)%.*3- O)*0#1#%'0#./-('*c$-S*'/0)3
K)S.0#'0)3-$2)%#1#%'0#./$ 2*.39%0-3)1#/)3@-3)1#/)3- 5)S9&'0.*4-1#&)$-./-2&'/
")0'#&)3-2*.q)%0-2&'/ ('0)*#'&$@-$922&4--%,'#/-'/3- 8'0)/0-'/3-&#%)/$#/S-#$$9)$-
8*.1#0'^#&#04-'$$)$$)3 &.S#$0#%$-%./%)20-)$0'^&#$,)3- %&)'*)3
2*.%)39*)$--'/3-*.^9$0/)$$ W#/'&-2*.39%0-*#$c-$0'0)()/0
)$0'^&#$,)3 D'9/%,-'%0#7#0#)$-2&'//)3-#/-3)0'#&
8*.q)%0-2&'/-923'0) 8*.1#0'^#&#04-%./1#*()3
8*.1#0'^#&#04-923'0)

;&1+)1+) ;&1+)1+):&#%):")/""?[ ;&1+)1+):&#%):"):#/%)%5 ;&")?"D"$5>7"/%)1+) `")'#/)7#4")1%[)`")#(") `")+"$$)%&") e"++5/+)
>(571+1/<[ 7#4"[);&")@"+%)'5/'">% 01/1+&"?[)J>"'101'#%15/+ ("#?B)%5)+"$$[ >(5?,'%[ $"#(/%[
Z1/?)5,%) &#+)@""/)1?"/%101"?)#/? &#D")@""/)7"%[
75("
#/?)<"%)@#'4 1%)1+)0"#+1@$"[
%5),+[
;<

C1#</5+%1'+)J,77#(B
[ +,)-3)7)&.2()/0-.1-/.7)&-`g"-0)$0$-#$-'/-#(2.*0'/0-S*.b0,-'/3-#//.7'0#./-
3*#7)*-1.*-0,)-`g"-#/39$0*4

[ +,)-2*.%)$$-1.*-3)7)&.2()/0-.1-/.7)&-`g"-0)$0$-#$-%.(2&)e-'/3-*#$c4-'/3-
*)a9#*)$-0,)-#/39$0*4-0.-#/0)*1'%)-b#0,-$0'c),.&3)*$-#/-'%'3)(#'@-0,)-
8,'*('-#/39$0*4-'/3-%.(2'/#)$-1.%9$$)3-./-^#.('*c)*-3#$%.7)*4-'/3-
3)7)&.2()/0?-O.&&'^.*'0#./-b#0,-.0,)*-#/39$0*4-$0'c),.&3)*$-#$-)$$)/0#'&-0.-
0,)-`g"-#/39$0*4

[ A'#/0'#/#/S-0,)-%9**)/0-0)$0-2.*01.&#.-./-)e#$0#/S-$4$0)($-'/3-3)7)&.2#/S-
'22&#%'0#./$-1.*-0,)$)-0)$0$-./-/)b-'/3-*)2&'%)()/0-$4$0)($-*)a9#*)$-
$#S/#1#%'/0-#/7)$0()/0@-&#(#0#/S-0,)-19/3$-'7'#&'^&)-1.*-#/7)$0()/0-#/-/.7)&-
0)$0$

[ O.(2'/#./-3#'S/.$0#%-0)$0$-'/3-0)$0$-^'$)3-./-^#.('*c)*$-9$)3-#/ 8,'*('-
3#$%.7)*4-'/3-%&#/#%'&-3)7)&.2()/0-2*.S*'($-b#&&-%./0*#^90)-$#S/#1#%'/0&4-0.-
0,)-2#2)&#/)-.1-/.7)&-`g"-0)$0$-#/-%.(#/S-4)'*$

[ 5.%,)-"#'S/.$0#%$-#$-%.((#00)3-0.-#//.7'0#./-0,*.9S,-0,)-()3#%'& 7'&9)-
2*.7#3)3-^4-/.7)&-`g"-0)$0$-'/3-b.*c$-%&.$)&4-b#0,-'-b#3)-*'/S)-.1-2'*0/)*$- ;J
0.-'%,#)7)-0,#$

35'&")m(5,>
Differentiation through Personalised Healthcare

[ +,)*)-'*)-$0#&&-('/4-%,'&&)/S)$-0.-.7)*%.()-#/-^#.('*c)*-
3#$%.7)*4@-7'&#3'0#./-'/3-%.(()*%#'&#E'0#./-

[ `/-$2#0)-.1-0,)$)-%,'&&)/S)$@-5.%,)-#$-%.((#00)3-0.-
8)*$./'&#$)3 Q)'&0,%'*)-f ^)%'9$)-#0_$-c)4-0.-.9*-(#$$#./-.1-
3)7)&.2#/S-#//.7'0#7)-()3#%#/)$-'/3-3#'S/.$0#%$-1.*-0,)-
^)/)1#0-.1-2'0#)/0$-'/3-$.%#)04

[ "#'S/.$0#%$-%'2'^#&#0#)$-'/3-0)%,/.&.S#)$-2&'4-'-%*9%#'&-*.&)-#/
3#$%.7)*#/S-i-,'*7)$0#/S-^#.('*c)*$

[ Q'7#/S-"#'S/.$0#%$_ %'2'^#&#0#)$-#/0)*0b#/)3-0,*.9S,.90-'&&-
$0'S)$-.1-3*9S-3)7)&.2()/0-#$-'-$#S/#1#%'/0-'37'/0'S)
;V

=#$>**&4,+#$?#,)+"%,-#
;I

Novel biomarkers for diagnostics and drug R&D: What is industry looking for?

Recomendados

Recomendados

Más contenido relacionado

La actualidad más candente

La actualidad más candente (19)

Destacado

Destacado (6)

Más de MaRS Discovery District

Más de MaRS Discovery District (20)

Novel biomarkers for diagnostics and drug R&D: What is industry looking for?